文献速递淋巴瘤造血干细胞移植与细胞治疗

自体造血干细胞移植治疗富含T细胞/组织细胞的大B细胞淋巴瘤:EBMT淋巴瘤工作组研究

Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study.
PubMed 文献 · Blood Adv · 2024-01-01

该回顾性注册研究纳入2016至2021年间在欧洲血液与骨髓移植学会数据库登记的成人复发/难治性富含T细胞/组织细胞的大B细胞淋巴瘤(THRLBCL)和弥漫大B细胞淋巴瘤(DLBCL)患者,分别有201例和5543例,均在接受首次自体造血干细胞移植时处于挽救治疗敏感状态。THRLBCL组2年无进展生存(PFS)为78% vs DLBCL组59%(P < .001),2年总生存(OS)为81% vs 74%(P = .02),2年复发率为16% vs 35%(P < .001)。多因素分析中THRLBCL组复发风险HR 0.46(95%CI 0.31-0.7)和PFS的HR 0.58(95%CI 0.41-0.82)仍显著,OS获益HR 0.78(95%CI 0.54-1.12)不显著;倾向性评分匹配分析验证了上述结果。作者认为自体造血干细胞移植是挽救治疗敏感的复发/难治性THRLBCL的有效治疗选择。

要点

  • THRLBCL患者auto-HCT后2年PFS 78% vs DLBCL 59%(P < .001),2年OS 81% vs 74%(P = .02)。
  • THRLBCL组2年复发率16% vs DLBCL组35%(P < .001)。
  • 多因素分析THRLBCL组复发风险HR 0.46(95%CI 0.31-0.7),PFS的HR 0.58(95%CI 0.41-0.82),OS的HR 0.78(95%CI 0.54-1.12)不显著。

核心结论

  • 作者认为自体造血干细胞移植是挽救治疗敏感的复发/难治性THRLBCL的有效治疗选择。

研究设计与样本

  • 回顾性注册研究,纳入2016至2021年间在欧洲血液与骨髓移植学会数据库登记的成人复发/难治性THRLBCL和DLBCL患者,均接受首次auto-HCT且经PET-CT评估为挽救治疗敏感状态。
  • 共纳入201例THRLBCL患者和5543例DLBCL患者,主要终点为移植后2年无进展生存(PFS)。

主要发现

  • THRLBCL组2年PFS为78% vs DLBCL组59%(P < .001),2年OS为81% vs 74%(P = .02),2年复发率为16% vs 35%(P < .001)。
  • 多因素分析中THRLBCL组复发风险HR 0.46(95%CI 0.31-0.7)和PFS的HR 0.58(95%CI 0.41-0.82)仍显著,OS获益HR 0.78(95%CI 0.54-1.12)不显著。
  • 倾向性评分匹配分析验证了上述结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although broadly used, consolidative autologous hematopoietic stem cell transplantation (auto-HCT) for relapsed/refractory (R/R) T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) has never been specifically investigated. Here, we have analyzed outcomes of auto-HCT for THRLBCL compared with diffuse large cell B-cell lymphoma not otherwise specified (DLBCL). Eligible for this retrospective registry study were adult patients with R/R THRLBCL and DLBCL, respectively, who underwent a first auto-HCT in a salvage-sensitive disease status as assessed by positron emission tomography-computed tomography between 2016 and 2021 and were registered with the European Society for Blood and Marrow Transplantation database. The primary end point was progression-free survival (PFS) 2 years after transplantation. A total of 201 patients with THRLBCL and 5543 with DLBCL were included. There were no significant differences in terms of disease status at HCT, pretreatment lines, and interval from diagnosis to transplant between the cohorts, but patients with THRLBCL were significantly younger, contained a higher proportion of men, and had a better performance status. Compared with DLBCL, THRLBCL was associated with significantly better 2-year PFS (78% vs 59%; P < .001) and overall survival (OS, 81% vs 74%; P = .02) because of a significantly lower 2-year relapse incidence (16% vs 35%; P < .001). On multivariate analysis, favorable relapse risk (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.31-0.7) and PFS (HR, 0.58; 95% CI, 0.41-0.82) of patients with THRLBCL remained significant, whereas OS benefits (HR, 0.78; 95% CI, 0.54-1.12) did not. These results were validated in a propensity score-matched analysis. These data prove auto-HCT as an effective treatment option for salvage-sensitive R/R THRLBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Renders S, Ngoya M, Finel H, et al. Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study. Blood Adv. 2024. PMID: 39213423. doi:10.1182/bloodadvances.2024013152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。